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COVID-19, caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), 
represents a global crisis. Key to SARS-CoV-2 therapeutic development is unraveling the 
mechanisms driving high infectivity, broad tissue tropism and severe pathology. Our 2.85Å cryo-
EM structure of SARS-CoV-2 spike (S) glycoprotein reveals that the receptor binding domains 5 
(RBDs) tightly bind the essential free fatty acid (FFA) linoleic acid (LA) in three composite 
binding pockets. The pocket also appears to be present in the highly pathogenic coronaviruses 
SARS-CoV and MERS-CoV. LA binding stabilizes a locked S conformation giving rise to reduced 
ACE2 interaction in vitro. In human cells, LA supplementation synergizes with the COVID-19 
drug remdesivir, suppressing SARS-CoV-2 replication. Our structure directly links LA and S, 10 
setting the stage for intervention strategies targeting LA binding by SARS-CoV-2.  
 
One Sentence Summary:  
The SARS-CoV-2 spike binds linoleic acid, a key molecule in inflammation, immune modulation 
and membrane fluidity.  15 
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Main Text:  
Seven coronaviruses are known to infect humans. The four endemic human coronaviruses OC43, 
229E, HKU1 and NL63 cause mild upper respiratory tract infections while pandemic virus SARS-
CoV-2, and earlier SARS-CoV and MERS-CoV, can cause severe pneumonia with acute 
respiratory distress syndrome, multi-organ failure, and death (1,2).  5 
SARS-CoV-2 has acquired functions that promote its harsh disease phenotype. SARS-CoV-2 
causes severe inflammation and damage to endothelial cells in the heart, kidneys, liver and 
intestines, suggestive of a vascular infection rather than a purely respiratory disease (3, 4). The 
attachment of SARS-CoV-2 to a host cell is initiated by the spike protein trimer (S), which 
decorates the outer surface of the virus, binding to its cognate receptor angiotensin-converting 10 
enzyme 2 (ACE2), with higher affinity than SARS-CoV (5-7). A S1/S2 polybasic furin protease 
cleavage site distinguishes SARS-CoV-2 from SARS-CoV or other closely related bat 
coronaviruses and serves to stimulate entry into host cells and cell-cell fusion (5, 8, 9). Inside the 
host cell, human coronaviruses remodel the lipid metabolism to facilitate virus replication (10). 
Infection by SARS-CoV-2 triggers an unusually impaired and dysregulated immune response (11) 15 
and a heightened inflammatory response (12) working in synergy with interferon production in the 
vicinity of infected cells to drive a feed-forward loop to upregulate ACE2 and further escalate 
infection (13).  
In the search for additional functions that contribute to the pathology of infection, we determined 
the structure of the SARS-CoV-2 S glycoprotein by cryo-EM (Fig. 1). We produced SARS-CoV-20 
2 S as a secreted trimer (14) in MultiBac (15) baculovirus-infected Hi5 insect cells (fig. S1, (16)). 
Highly purified protein was used for cryo-EM data collection (fig. S2, table S1). After 3D 
classification and refinement without applying symmetry (C1) we obtained a 3.0 Å closed 
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conformation from 136,405 particles and a 3.5 Å open conformation with one receptor-binding 
domain (RBD) in the up position from 57,990 particles (figs. S2, S3). C3 symmetry was applied 
to the closed conformation particle pool yielding a 2.85 Å map (Fig.1A, figs. S2, S3).  
The structure of S displays the characteristic overall shape observed for coronavirus S proteins in 
the closed and open conformations (17-19)  with the closed form (~70%) predominating in our 5 
data set (Fig.1A, figs. S2-S4). Model building of the closed form revealed additional density in the 
RBDs in our structure (Fig.1B). The tube-like shape of this density was consistent with a fatty 
acid, with size and shape similar to LA bound to other proteins (Fig.1B, fig. S5) (20, 21). Liquid 
chromatography coupled ESI-TOF mass spectrometry (LS-MS) analysis confirmed the presence 
of a compound with the molecular weight of LA in our purified sample (Fig.1C).  10 
Hallmarks of FFA-binding pockets in proteins are an extended ‘greasy’ tube lined by hydrophobic 
amino acids which accommodates the hydrocarbon tail, and a hydrophilic, often positively charged 
anchor for the acidic headgroup of the FFA. In our structure, a hydrophobic pocket mostly shaped 
by phenylalanines forms a bent tube into which the LA fits well (Fig. 1D,E). The anchor for the 
headgroup carboxyl is provided by an arginine (R408) and a glutamine (Q409) from the adjacent 15 
RBD in the trimer, giving rise to a composite LA-binding site (Fig. 1E). We confirmed the 
presence of LA in all three binding pockets in the S trimer in the unsymmetrized (C1) closed 
structure (fig. S6). Similarly, masked 3D classification focusing on the RBD domains could not 
identify any unoccupied pockets (fig. S7).  
Our S construct contains alterations as compared to native SARS-CoV-2 S namely addition of a 20 
trimerization domain and deletion of the polybasic cleavage site, neither of which alter S 
conformation appreciably (14, 17) (fig. S8). Glycosylation sites are located away from the LA-
binding pocket and largely native in our structure (7, 17) (table S2). Thus, neither mutations nor 
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glycosylation are likely to impact the LA-binding pocket. We compared S and RBD produced in 
insect cells with mammalian produced S to identify any potential influence of differences in 
glycosylation on ACE2 binding by competition enzyme-linked immunosorbent assay (ELISA) 
(Fig. 2A). All three reagents bound ACE2 efficiently. We further confirmed ACE2 binding by S 
using SEC with purified proteins (Fig. 2B). The LA-binding pocket and the receptor binding motif 5 
(RBM) are distal and non-overlapping (Fig. 2C). Notably, in the LA-bound S the RBM is ordered 
and buried at the interface between RBDs while it was disordered in previously described SARS-
CoV-2 S cryo-EM structures (7, 17).  
SARS-CoV-2 S can also adopt an open conformation (fig. S4) which is compatible with binding 
ACE2. In previous apo S cryo-EM structures about 60-75% of the S trimers were in the open 10 
conformation (7, 17), contrasting our observation of ~70% in the closed conformation. This could 
be due to LA stabilizing the closed conformation, and if so LA would be expected to reduce ACE2 
binding. We performed surface plasmon resonance (SPR) experiments with biotinylated ACE2 
immobilized on a streptavidin-coated chip (Fig. 2D, fig. S9). We first determined the KD of the 
RBD / ACE2 interaction to validate our assay. Our value (26 nM, fig. S9C) is in good agreement 15 
with previous studies (44 nM, (22)) obtained by SPR with the RBD immobilized and ACE2 as 
analyte. Apo S was prepared by applying Lipidex, the established method for removing lipids from 
lipid-binding proteins (23). A KD of 0.7 nM was obtained for the apo S / ACE2 interaction (fig. 
S9A). For the LA-bound S / ACE2 interaction we obtained a KD of 1.4 nM (fig. S9B). We 
consistently obtained a markedly reduced resonance unit (RU) signal for LA-bound S as compared 20 
to apo S at the same concentrations (Fig. 2D, fig. S9A,B). This correlates with the apo state having 
a higher percentage of S trimers in the open, ACE2-accessible conformation.  
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We characterized the affinity of the LA interaction both experimentally and computationally. Our 
SPR assays utilizing immobilized RBD yielded a binding constant of ~41 nM exhibiting a slow 
off-rate, consistent with tight binding of LA (fig. S10). Repeated molecular dynamics simulations 
of the entire locked LA-bound spike trimer (3 x 100 ns) using GROMACS-2019 (24) corroborated 
the persistence of stable interactions between LA and the spike trimer (Movies S1,S2). The affinity 5 
of LA binding to the spike trimer will likely be higher than to the RBD alone, taking into account 
polar headgroup interactions with R408 and Q409 of the adjacent RBD (Fig. 1E). The resolution 
of the RBDs in our open S cryo-EM structure was insufficient to either assign, or rule out, a ligand-
bound pocket (fig. S3). However, the slow off-rate observed with the RBD monomer (fig. S10) 
suggests that LA binding could be maintained when the S trimer transiently converts into the open 10 
conformation. This is supported by our observation that LA was retained during S purification in 
spite of S trimers adopting the open form ~30% of the time (fig. S2) and by our MD simulations 
with a modelled ligand-bound open spike trimer (Movie S3) in which all three LAs remained 
bound over 500 ns.  
Next, we investigated the effect of LA in experiments using live SARS-CoV-2 virus to infect 15 
human epithelial cells. Remdesivir is an RNA-dependent RNA polymerase inhibitor and the first 
anti-viral drug showing benefit in the treatment of COVID-19 in clinical trials, albeit with 
considerable side effects at the doses required (25). LA supplementation at 50-100 µM 
concentrations was previously shown to affect coronavirus entry and replication (10). We 
administered remdesivir at 20, 64 and 200 nM concentration, supplementing with 50 µM LA (Fig. 20 
2E). Our results revealed synergy, with the dose of remdesivir required to suppress SARS-CoV-2 
replication markedly reduced by adding LA (Fig. 2E,F). 
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We superimposed our LA-bound structure on previous SARS-CoV-2 apo S structures in the closed 
conformation (7, 17) and identified a gating helix located directly at the entrance of the binding 
pocket (Fig. 3A-C). This gating helix, comprising Ty365 and Tyr369, is displaced by about 6 Å 
when LA is bound, thus opening the pocket (Fig.3A,B). In the apo SARS-CoV-2 S trimer (7, 17), 
a gap between adjacent RBDs places the hydrophilic anchor residues ~10 Å away from the position 5 
of the LA headgroup (Fig. 3C). Upon LA binding, the adjacent RBD in the trimer moves towards 
its neighbor, and the anchor residues Arg408 and Gln409 lock down on the headgroup of LA (Fig. 
3C,D). Overall, this results in a compaction of trimer architecture in the region formed by the three 
RBDs giving rise to a locked S structure (Fig. 3D, Movie S4).  
We investigated whether the LA-binding pocket is conserved in the seven coronaviruses that infect 10 
humans (Fig. 4A, table S3). Sequence alignment shows that all residues lining the hydrophobic 
pocket and the anchor residues (Arg408/Gln409) in SARS-CoV-2 are fully conserved in SARS-
CoV (Fig. 4A). Structural alignment of LA-bound RBDs within the trimer of SARS-CoV-2 and 
‘apo’ SARS-CoV RBDs (19) reveals that the LA-binding pocket is present in SARS-CoV. The 
greasy tube is flanked by a gating helix as in SARS-CoV-2, with Arg395/Gln396 of SARS-CoV 15 
positioned 10Å and 11Å from the entrance, respectively, virtually identical to apo SARS-CoV-2 
(Fig. 3C,4B).  In MERS-CoV, the gating helix and hydrophobic residues lining the pocket are also 
present. Tyr365, Tyr369 and Phe374 are substituted by likewise hydrophobic leucines and a valine, 
respectively (Fig. 4A,C) (19). The Arg408/Gln409 pair is not conserved, however, we identify 
Asn501/Lys502 and Gln466 as potential anchor residues, located on a β-sheet and an α-helix 20 
within the adjacent RBD, up to 11Å away from the entrance (Fig. 4C). Thus, the greasy tube and 
hydrophilic anchor appear to be present in MERS-CoV, suggesting convergent evolution.  In 
HCoV OC43, gating helix and hydrophobic residues lining the pocket are largely conserved, while 
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Tyr365, Tyr369 and Phe374 are replaced by methionines and alanine, respectively (Fig. 4A) (18). 
Arg413 is located on the same helix as Arg408/Gln409 in SARS-CoV-2 and could serve as a 
hydrophilic anchor (Fig. 4D). No gap exists in this presumed ‘apo’ form structure between the 
RBDs which appear already in the locked conformation (Fig. 4D, fig. S11 (18)).  In HCoV HKU1, 
the hydrophobic residues are again largely conserved, but a charged residue (Glu375) is positioned 5 
directly in front of the entrance, obstructing access for a putative ligand (Fig. 4E) (26). The RBDs 
of HCoVs 229E and NL63 adopt a very different fold (fig. S13) (27, 28), and many of the LA-
binding residues are not present (Fig. 4A), hampering predictions of a binding site for fatty acids.   
In summary, we find four molecular features mediating LA binding to SARS-CoV-2, and 
potentially also SARS-CoV and MERS-CoV S proteins: a conserved hydrophobic pocket, a gating 10 
helix, amino acid residues pre-positioned to interact with the LA carboxy headgroup, and loosely 
packed RBDs in the ‘apo’ form. In contrast, in each of the four common circulating HCoVs, it 
appears that one or more of these four architectural prerequisites are lacking in the S protein 
structures (Fig. 4, figs. S11,S12). LA binding to SARS-CoV-2 S triggers a locking down of the 
hydrophilic anchor and a compaction of the RBD trimer (Fig. 3C,D). In addition to stabilizing the 15 
closed conformation, this could also help stabilize the S1 region comprising the N-terminal domain 
and the RBD. The RBM, central to ACE2 binding, appears to be conformationally preorganized 
in our structure (Fig. 2C) indicating a generally more rigid RBD trimer when LA is bound. While 
direct crosstalk in between the LA-binding pocket and the RBM is not apparent from our structure 
(Fig. 2C), the conformational changes in the RBD trimer (Fig. 3) could impact ACE2 docking and 20 
infectivity as indicated by our SPR assays showing reduced levels of S binding in the presence of 
LA (Fig. 2D). The S protein's tight binding of LA originates from a well-defined size and shape 
complementarity afforded by the pocket (Fig. 1B,D). The LA-binding pocket thus presents a 
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promising target for future development of small molecule inhibitors that, for example, could 
irreversibly lock S in the closed conformation and interfere with receptor interactions. It is 
noteworthy in this context that a fatty acid binding pocket was exploited previously to develop 
potent small molecule anti-viral drugs against rhinovirus, locking viral surface proteins in a 
conformation incompatible with receptor binding (29, 30). These anti-virals were successful in 5 
human clinical trials (31, 32).  
A recent proteomic and metabolomic study of COVID-19 patient sera showed continuous decrease 
of FFAs including LA (33). Lipid metabolome remodeling is a common element of viral infection 
(34, 35). For coronaviruses, the LA to arachidonic acid metabolic pathway was identified as central 
to lipid remodeling (10). We hypothesize that LA sequestration by SARS-CoV-2 could confer a 10 
tissue-independent mechanism by which pathogenic coronavirus infection may drive immune 
dysregulation and inflammation (35-37). Our findings provide a direct structural link between LA, 
COVID-19 pathology and the virus itself and suggest that both the LA-binding pocket within the 
S protein and the multi-nodal LA signaling axis, represent excellent therapeutic intervention points 





  20 
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Figure 1. Cryo-EM structure of SARS-CoV-2 spike linoleic acid complex. (A) Cryo-EM 
density of spike trimer (left). Monomers in cyan, green and pink, respectively. The structure in a 
cartoon representation in a front (middle) and top view (right). Bound LA illustrated as spheres 
colored in orange. One LA-binding pocket is boxed in red. (B) Composite LA-binding pocket 5 
formed by adjacent RBDs. Tube-shaped EM density is shown. (C) LC-MS of purified S. Chemical 
structure and molecular weight of LA (top), C4 column elution profile (middle) and ESI-TOF of 
wash solution (grey) and C4 peak elution fraction (black) with peak molecular weight indicated 
(bottom). (D) Hydrophobic LA-binding pocket in a surface representation illustrating excellent fit 
of bound LA (orange, sticks and balls representation). Blue and red indicate positive and negative 10 
surface charge, respectively. (E) LA interactions with amino acids in the binding pocket. The 
acidic LA headgroup is in the vicinity of an arginine (408) and a glutamine (409). 
 
Figure 2. Functional characterization of LA-bound SARS-CoV-2 spike. (A) Insect cell (Hi5) 
expressed spike (dark blue bars), insect cell expressed RBD (light blue bars) and mammalian 15 
(HEK293) expressed spike (white bars) in competition ELISAs utilizing immobilized ACE2. Error 
bars: standard deviations, three replicates. (B) LA-bound SARS-CoV-2 spike protein interaction 
with ACE2 was analyzed by size exclusion chromatography evidencing complex formation. SEC 
profiles (left) for ACE2 (yellow, III), LA-bound spike (green, II) and a mixture of ACE2 and LA-
bound spike (orange, I) are shown. Peak fractions (I.-III.) were analyzed by SDS-PAGE 20 
evidencing the expected proteins (right). (C) LA-bound S glycoprotein trimer top view with RBDs 
shown in cyan, green and pink respectively (left). In each RBD subunit the motif responsible for 
ACE2 binding (RBM) is in red, and LA is shown as spheres colored in orange. A close-up view 
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into the cyan RBD (right) shows that the RBM is fully ordered, and LA and RBM are not in direct 
contact. (D) SPR analysis of the binding of LA-bound spike trimer (orange curves) and apo spike 
trimer (green curves) to immobilized ACE2. Apo spike and LA-bound spike were diluted to 
concentrations of 40 nM and 160 nM, respectively. Black lines correspond to a global fit using a 
1:1 binding model.  (E) Synergistic effect of LA and remdesivir on SARS-CoV-2 viral replication. 5 
Effects of varying doses of remdesivir +/- 50 µM LA on virus infection are shown. Human Caco-
2 ACE2+ cells were infected with SARS-CoV-2 and then treated with varying doses of remdesivir 
+/- 50 µM LA. At 96h post-infection, cells were fixed and infected cells detected by 
immunofluorescence assay using an anti-N antibody (green). Cell nuclei were stained by DAPI 
(blue). Representative images corresponding to the remdesivir dose range 20 – 200 nM are shown. 10 
(F) The amount of extracellular virus present in wells (n=3) at the dose combinations shown was 
determined by qRT-PCR. 
 
Figure 3. Comparison of LA-bound and apo S structures. (A) Superimposition of LA-bound 
SARS-CoV-2 (cyan RBD) and the ligand-free ‘apo’ RBD (grey) (PDBID 6VXX, (7)). The gating 15 
helix at the entrance of the hydrophobic pocket moves by 6 Å in the presence of LA. Tyr365 and 
Tyr369 swing away avoiding clashes with LA (orange). Black arrows indicate the rearrangements. 
(B) The same structure as panel A rotated by 90⁰ as indicated, showing the entrance of the 
hydrophobic pocket. (C) Formation of a composite LA-binding pocket by two adjacent RBDs in 
LA-bound S involves a ~5 Å movement of RBD2 (green) towards RBD1 (cyan) compared to apo 20 
S (grey). (D) Superimposition of the RBD trimer of apo S (grey) and LA-bound S (RBD1 cyan, 
RBD2 green, RBD3 pink, LA orange) is shown (left). The individual RBD trimers are depicted 
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for LA-bound S (right, top) and apo S (right, bottom) with RBDs boxed in black, highlighting the 
compaction of RBDs in the LA-bound S structure.  
 
Figure 4. Human coronavirus RBD architectures.  (A) Alignments of the seven CoV strains 
that can infect humans, highlighting conserved residues. Residues lining the hydrophobic pocket 5 
are underlaid (cyan). Gating helix residues are marked (purple). Residues positioned to interact 
with the LA polar headgroup are underlaid in green. Glu375 in HKU1 is underlaid in red (cf. panel 
E). (B) Superimposition of RBD1 of LA-bound SARS-CoV-2 (RBD2 in green) with RBD1 of 
ligand free ‘apo’ SARS-CoV (RBD1 and RBD2 magenta, PDBID 5X58 (19)) indicates a 
conservation of the composite binding pocket. (C) Superimposition of RBD1 of LA-bound SARS-10 
CoV-2 (RBD2 is omitted for clarity) with RBD1 of MERS-CoV (RBD1 and RBD2 forest green, 
PDBID 5X5F (19)). (D) Superimposition of RBD1 of LA-bound SARS-CoV-2 (RBD2 in green) 
with RBD1 of OC43 (RBD1 and RBD2 purple, PDBID 6NZK, (18)). (E) Superimposition of LA-
bound SARS-CoV-2 RBD with HKU1 RBD (brown, PDBID 5GNB (26)). LA is omitted in SARS-
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Materials and Methods 
Protein production.  
SARS-CoV-2 spike protein. The pFastBacDual plasmid for SARS-CoV-2 S ectodomain for 
expression in insect cells (14) was kindly provided by Florian Krammer (Icahn School of 
Medicine, USA). In this construct, S comprises amino acids 1 to 1213 and is fused to a C-terminal 5 
thrombin cleavage site followed by a T4-foldon trimerization domain and a hexahistidine affinity 
purification tag. The polybasic cleavage site has been deleted (RRAR to A) in the construct (14). 
Protein was produced with the MultiBac baculovirus expression system (Geneva Biotech, Geneva, 
Switzerland) (41) in Hi5 cells using ESF921 media (Expression Systems Inc.). Supernatants from 
transfected cells were harvested 3 days post-transfection by centrifugation of the culture at 1,000g 10 
for 10 min followed by another centrifugation of supernatant at 5,000g for 30 min. The final 
supernatant was incubated with 7 ml HisPur Ni-NTA Superflow Agarose (Thermo Fisher 
Scientific) per 3 liters of culture for 1h at 4ºC. Subsequently, a gravity flow column was used to 
collect the resin bound with SARS-CoV-2 spike protein, the resin was washed extensively with 
wash buffer (65 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 7.5), and the protein was 15 
eluted using a step gradient of elution buffer (65 mM NaH2PO4, 300mM NaCl, 235mM imidazole, 
pH 7.5). Elution fractions were analyzed by reducing SDS-PAGE and fractions containing SARS-
CoV-2 spike protein were pooled, concentrated using 50 kDa MWCO Amicon centrifugal filter 
units (EMD Millipore) and buffer-exchanged in phosphate-buffered saline (PBS) pH 7.5. 
Concentrated SARS-CoV-2 S was subjected to size exclusion chromatography (SEC) using a 20 
Superdex 200 increase 10/300 column (GE Healthcare) in PBS pH 7.5. Peak fractions from SEC 
were analyzed by reducing SDS-PAGE and negative stain electron microscopy (EM); fraction 7 
was used for cryo-EM (fig.S1). 
Lipidex-treated SARS-CoV-2 spike protein. Purified SARS-CoV-2 spike protein was treated with 
lipidex-1000 resin (Perkin Elmer; cat no. 6008301) according to published protocols (23, 42, 43). 25 
Briefly, S was incubated with lipidex-1000 resin pre-equilibrated in PBS pH 7.5 overnight at 4℃ 
on a roller shaker. Subsequently, lipidex-treated S was separated from the resin using a gravity 
flow column. Integrity of the protein was confirmed by size exclusion chromatography (SEC) 
using a S200 10/300 increase column (GE Healthcare) and SDS-PAGE. 
ACE2 protein. The gene encoding for the ACE2 ectodomain (amino acids 1 to 597) was codon 30 
optimized for insect cell expression, synthesized (Genscript Inc., New Jersey USA) and inserted 
into pACEBac1 plasmid (Geneva Biotech, Geneva, Switzerland). The resulting construct 
pACEBac1_MelACE2his construct contains an N-terminal melittin signal sequence for secretion 
and a C-terminal octa-histidine affinity purification tag. ACE2 protein was produced and purified 
following the same protocol as for spike protein. 35 
Biotinylated ACE2 protein. ACE2 was modified by inserting a synthetic DNA between the StuI 
and HindIII restriction sites in pACEBac1-MelACE2his giving rise to a modified C-terminus 
including a linker (amino acid sequence GGSGSG) followed by avi tag (amino acid sequence 
GLNDIFEAQKIEWHE), a second linker (amino acid sequence GGSGG) and an octa-histidine 
tag for purification. Avi-tagged ACE2 was produced using the same protocol as for ACE2 protein. 40 
Biotinylation was achieved by incubation with BirA in the presence of biotin according to 
established protocols (44). Remaining free biotin and BirA were removed by purifying biotinylated 
ACE2 using Ni-NTA Superflow Agarose followed by size exclusion chromatography (SEC) using 
a S200 10/300 increase column (GE Healthcare). 
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Receptor Binding domain (RBD) and biotinylated RBD. The gene encoding for the SARS-CoV-2 
receptor binding domain (amino acids R319 to F541), fused at its N-terminus to the native spike 
signal sequence (amino acid sequence MFVFLVLLPLVSSQ), was codon optimized for insect cell 
expression, synthesized (Genscript Inc., New Jersey USA) and inserted into pACEBac1 plasmid 
(Geneva Biotech, Geneva, Switzerland). The resulting construct pACEBac1-RBDhis comprises a 5 
C-terminal octa-histidine affinity purification tag. Protein was produced and purified as described 
for spike trimer. Biotinylated RBD was generated by adding an avi tag for BirA mediated 
biotinylation as described above for biotinylated ACE2. Lipidex-treated biotinylated RBD was 
then prepared as described above for lipidex-treated S.  
 10 
Negative stain sample preparation and microscopy 
4 µL of 0.05 mg/mL SARS-CoV-2 spike protein was applied onto a freshly glow discharged (1 min 
at 10 mA) CF300-Cu-50 grid (Electron Microscopy Sciences), incubated for 1 min, and manually 
blotted. 4 µL of 3% Uranyl Acetate was applied onto the same grid and incubated for 1 min before 
the solution was blotted off. The grid was loaded onto a FEI Tecnai 12 120 kV BioTwin Spirit 15 
TEM. Images were acquired at a nominal magnification of 49,000x. 
 
Cryo-EM sample preparation and data collection  
4 µL of 1.25 mg/mL SARS-CoV-2 spike protein was loaded onto a freshly glow discharged (2 min 
at 4 mA) Quantifoil R1.2/1.3 carbon grid (Agar Scientific), blotted using a Vitrobot MarkIV 20 
(Thermo Fisher Scientific) at 100% humidity and 4°C for 2 s, and plunge frozen. Data were 
acquired on a FEI Talos Arctica transmission electron microscope operated at 200 kV and 
equipped with a Gatan K2 Summit direct detector and Gatan Quantum GIF energy filter, operated 
in zero-loss mode with a slit width of 20 eV using the EPU software.  
Data were collected in super-resolution at a nominal magnification of 130,000x with a virtual pixel 25 
size of 0.525 Å. The dose rate was adjusted to 6.1 counts/physical pixel/s. Each movie was 
fractionated in 55 frames of 200 ms. 3289 micrographs were collected in a single session with a 
defocus range comprised between -0.8 and -2 µm.  
 
Cryo-EM data processing  30 
The dose-fractionated movies were gain-normalized, aligned, and dose-weighted using 
MotionCor2 (45). Defocus values were estimated and corrected using CTFFIND4 (46). 611,879 
particles were automatically picked using Relion 3.0 software (47). Reference-free 2D 
classification was performed to select well-defined particles, after four rounds of 2D classification 
a total of 386,510 good particles were selected for further 3D classification. An initial model was 35 
generated using 50,000 particle images in Relion 3.0, and the selected particles from 2D 
classification were subjected to 3D classification using 8 classes. Classes 4 and 6 (fig. S2), showing 
prominent features representing a total of 202,082 particles were combined and used for 3D 
refinement. The 3D refined particles were then subjected to a second round of 3D classification 
using 5 classes. Class 4 and 5 were combined for the closed conformation map, class 3 represented 40 
the open conformation, comprising 136,405 and 57,990 particles respectively. The selected maps 
were subjected to 3D refinement without applying any symmetry with respective 3D models. The 
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maps were subsequently subjected to local defocus correction and Bayesian particle polishing in 
Relion 3.0. Global resolution and B factor (-89 Å2 and -116 Å2 for closed and open maps 
respectively) of the map were estimated by applying a soft mask around the protein density, using 
the gold standard Fourier shell correlation (FSC) = 0.143 criterion, resulting in an overall 
resolution of 3.03 Å and 3.7 Å respectively. The open map was imported into Relion 3.1 software, 5 
where it was further corrected for higher-order aberrations and magnification anisotropy. This 
yielded a final resolution of 3.5 Å (B factor of -87 Å2). C3 symmetry was applied to the closed 
conformation map using Relion 3.0, followed by 3D classification using 3 classes. Class 3 with 
217,815 particles was selected for CTF refinement and Bayesian polishing, yielding a final 
resolution of 2.85 Å (B factor of -86.8 Å2). Local resolution maps were generated using Relion 3.0 10 
(fig. S3). 
 
Cryo-EM model building and analysis  
UCSF Chimera (48) and Coot (49) were used to fit atomic models (PDBID 6VXX, (7)) into the 
cryo-EM map. The model was subsequently manually rebuilt using Coot and the closed 15 
conformation map. This closed conformation model was used to build features specific of the open 
conformation map and to further improve the model by using the C3-symmetrized map. To guide 
the model building, sharpened (50) and unsharpened maps were used in different steps of the 
process. N-linked glycans were hand-built into the density where visible, and restraints for non-
standard ligands were generated with eLBOW (51). The model for the closed conformation was 20 
real space refined with Phenix (52) and the quality was additionally analyzed using MolProbity 
(53) and EMRinger (54), to validate the stereochemistry of the components. The quasi-atomic 
model of the open conformation was generated by first fitting the atomic model of the closed 
conformation into the open cryo-EM map using UCSF Chimera. We then used COOT and UCSF 
Chimera to move one RBD into the open conformation, by aligning this RBD to the atomic model 25 
of a published open form of SARS-CoV-2 S (PDBID 6VSB, (17)). Finally, this open model was 
fitted into the cryo-EM open map with COOT and UCSF Chimera. Figures were prepared using 
UCSF Chimera and PyMOL (Schrödinger, Inc.). 
 
Masked 3D classification in Relion 30 
The refined C3 particles stack was expanded 3-fold according to C3 symmetry in Relion. The 
symmetry expanded particle stack was then used as input for the masked 3D classification with 
the focus mask corresponding to NTD-RBD region created by one NTD and one RBD from 
neighbouring subunits. The same procedure was performed with refined C1 particles without 
particle expansion, applying 3 masks, one for each NTD-RBD pair. Masked 3D classification was 35 
performed without alignment using 5 classes for C3 particle and 3 classes for C1 particle data sets. 
Visual inspection of the 3D classes showed ~80% of the RBD’s clustered in class 3 in C3 and in 
class 1 in C1 with LA bound in the hydrophobic pocket. 
 
Mass spectrometry analysis 40 
For mass spectrometry analysis, a Bruker maXis II ETD quadrupole-time-of-flight instrument with 
electrospray ionization (ESI) coupled to a Shimadzu Nexera HPCL was used. In order to extract 
the fatty acids from the protein sample, a chloroform extraction protocol was performed. For this, 
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100 μl of the protein sample was mixed with 400 μl chloroform for 2 hours on a horizontal shaker 
in a teflon-sealed glass vial at 25°C. The organic phase was then transferred to a new glass vial 
and the chloroform was evaporated for 30 min in a desiccator. Subsequently, 50 μl of a 20% (v/v) 
acetonitrile solution was added to dissolve the fatty acids. From this solution, a 1:100 dilution in 
20% (v/v) acetonitrile was prepared and 20 μl were injected for LC-MS analysis. The samples 5 
were passed over a Phenomenex C4 Aeris column (100 × 2.1 mm, 3.6 μm, 200 Å) heated to 50°C 
using a gradient of 20% A to 98% B in 5 min (solvent A: H2O + 0.1% formic acid; solvent B/: 
ACN + 0.1% formic acid). The system was operated with Bruker’s O-TOF Control (V4.1) and 
Hystar (V4.1) software and data analysis as well as data post-processing was performed with 
Bruker’s DataAnalysis software (V4.4, SR1). 10 
 
ELISA activity assay 
The SARS-CoV-2 sVNT kit was obtained from GenScript Inc. (New Jersey, USA) for ELISA 
activity assays. Serial dilution series were prepared (from 0-4096 nM) of purified SARS-CoV-2 
spike proteins and RBD in PBS pH 7.5. This dilutions series was mixed with the same amount of 15 
HRP-RBD and incubated at 37ºC for 30 min. The mixtures were then added to ELISA plate wells, 
coated with ACE2 according to the manufacturer’s protocol. Triplicates of each sample were 
made. The ELISA plate was then incubated at 37ºC for 15 min and subsequently washed 4 times 
with wash buffer. The signal was then developed by adding TMB solution to each well, incubating 
15 minutes in the dark, followed by adding stop solution. The absorbance at 450 nm was 20 
immediately recorded. The data was plotted using Microsoft excel. The standard deviation of 
triplicates was added as error bars.    
 
SARS-CoV-2 spike / ACE2 interaction analysis, size exclusion chromatography (SEC)   
Purified SARS-CoV-2 spike and ACE2 proteins were combined in PBS pH 7.5 at a molar ratio of 25 
1:1.5 spike trimer to ACE2 monomer. The mixture was incubated on ice for 2 hours and subjected 
to SEC using a Superdex 200 increase 10/300 column (GE Healthcare) equilibrated in PBS pH 
7.5. Purified SARS-CoV-2 spike protein and ACE2 proteins were individually run on the same 
column in the same buffer as controls. The contents of peak fractions were analyzed by reducing 
SDS-PAGE.  30 
 
Surface plasmon resonance (SPR) experiments  
Interaction experiments using surface plasmon resonance (SPR) were carried out with a Biacore 
T200 system (GE Healthcare) according to the manufacturer’s protocols and recommendations. 
For RBD / ACE2 interaction measurements, purified biotinylated ACE2 was immobilized on a 35 
streptavidin coated (SA) chip (GE Healthcare) at ~300 response units (RUs). Purified RBD was 
serially diluted and injected at  concentrations 80 nM, 120 nM, 140 nM and 160 nM. Measurements 
were carried out in triplicates. For measuring ACE2 interactions with S and lipidex-treated S, 
respectively, purified biotinylated ACE2 was immobilized at ~50 RUs and purified proteins 
serially diluted and injected at concentrations of 40 nM, 60 nM, 80 nM, 120 nM and 160 nM. For 40 
LA / RBD measurements, biotinylated RBD was immobilized at ~3800 RUs as required, according 
to our calculations, for a sufficiently prominent signal upon binding of the small molecule LA 
(MW 280 Da). LA was purchased as a sodium salt (Sigma Aldrich, cat no. L8134) and dissolved 
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in PBS pH 7.5 at a concentration of 10 µM, serially diluted and injected at concentrations 4 µM, 
6 µM, 8 µM  and 10 µM. Running buffer for all measurements was PBS buffer pH 7.5. Sensorgams 
were analyzed and KD, kon and koff values in all SPR experiments determined with the Biacore 
Evaluation Software (GE Healthcare), fitting the raw data using a 1:1 binding model. 
 5 
Live SARS-CoV-2 experiments 
Cell culture. A Vero E6 cell line modified to constitutively express the serine protease TMPRSS2 
(Vero E6/TMPRSS2; (9) (obtained from NIBSC, UK) and the human gut epithelial cell line Caco-
2 expressing ACE2 (Caco-2-ACE2) (a kind gift of Dr Yohei Yamauchi, University of Bristol) 
were cultured at 37⁰C in 5% CO2 in Dulbecco’s modified Eagle’s medium plus GlutaMAX 10 
(DMEM, Gibco, ThermoFisher) supplemented with 10% fetal bovine serum (FBS, Gibco, 
ThermoFisher) and 0.1 mM non-essential amino acids (NEAA, Sigma Aldrich).  
SARS-CoV-2 viral propagation. A stock of infectious virus was produced by inoculation of Vero 
E6/TMPRSS cells with the SARS-CoV-2 isolate SARS-CoV-
2/human/Liverpool/REMQRQ0001/2020 (55) in infection medium (Eagle’s minimum essential 15 
medium plus GlutaMAX (MEM, Gibco, ThermoFisher) supplemented with 2% FBS and NEAA).  
Cells were incubated at 37⁰C in 5% CO2 for 72 hours before being harvested and filtered through 
a 0.2 µm filter. The viral titer was determined by TCID50 on Vero E6 cells as previously described 
(56).  
SARS-CoV-2 infection assay. Caco-2-ACE2 cells were seeded for 18 hours in DMEM in µClear 20 
96-well Microplates (Greiner Bio-one). The culture supernatant was removed and cells were 
infected with SARS-CoV-2 diluted in infection medium to a MOI of 0.1 for 1 hour. The virus was 
removed and replaced with infection medium containing eight-fold serial dilutions of LA, 
remdesivir (RMD; Cambridge Bioscience, UK) or LA+RMD. After 96 hours incubation at 37⁰C 
in 5% CO2, supernatants were collected for qRT-PCR and cells fixed in 4% PFA for 60 minutes 25 
for image analysis. All work with infectious SARS-CoV-2 virus was conducted in a Class III 
microbiological safety cabinet in a containment level 3 facility at the University of Bristol.  
Cell viability assay. Cell viability and compound toxicity were determined by MTT assay. Samples 
were treated identically to viral infection assays, with the exclusion of the viral inoculation step. 
After 96 hours incubation at 37⁰C, media was removed and replaced by Thiazolyl Blue 30 
Tetrazolium Bromide (MTT; Sigma Aldrich) solution (1 mg/ml) and incubated for 3 hours at 37⁰C. 
The MTT reagent was then removed and cells lysed by addition of 100% ethanol. Samples were 
analyzed by reading the absorbance at 600 nm. 
qRT-PCR. Culture supernatants were collected and RNA extracted using the QIAamp Viral RNA 
Isolation kit (Qiagen) according to the manufacturer’s instructions with elution of RNA in 60 µl 35 
of AVE solution. 5 µl of each sample was used for qRT-PCR analysis using a TaqPathTM 1-Step 
RT-qPCR Master Mix, CG (Applied Biosystems, ThermoFisher) following the manufacturer’s 
instructions and the previously described SARS-CoV-2 E gene primer set (57) using a Mx3005P 
Real-Time PCR System (Agilent). SARS-CoV-2 RNA genome equivalence was determined using 
the MxPro qPCR Software (Agilent) and RNA extracted from titered virus and a AccuPlexTM 40 
SARS-CoV-2 Reference Material Kit (SeraCare, Milford, US) as standards. 
Immunofluorescence analysis. Fixed cells were stained for DAPI (Sigma Aldridge) and SARS-
CoV-2 nucleocapsid (N) protein (200-401-A50, Rockland) following permeabilization with 
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Triton-X100 and blocking with BSA. Images were acquired on the ImageXpress Pico Automated 
Cell Imaging System (Molecular Devices) using the 10X objective. Stitched images of 9 fields 
covering the central 36% of the well were analyzed for infected cells using Cell Reporter Xpress 
software (Molecular Devices). Briefly, cell number was determined by automated counting of 
DAPI stained nuclei, infected cells are determined as those cells in which positive N staining was 5 
detected associated with a nuclei. The percentage of infected cells relative to control wells in which 
no drug was added (virus only) were calculated and variable slope non-linear fit curves were 
assigned using GraphPad Prism v8.4.3.  
 
Computational Studies  10 
Modelling 
Loops for the unstructured regions of the locked (linoleic acid bound) and open (apo) cryo-EM 
structures were built using UCSF Chimera (48). Disulphide bonds within reasonable reach were 
reconstructed (42 for the closed structure and 43 for the open) and each chain sequence was used 
in an EBI-blast check to verify wild type spike sequence post build. Procheck (58) was then used 15 
to check the quality of the resulting structure prior to simulation. Acpype (59) was used to prepare 
the topologies for the linoleic acid. 
 
Molecular Dynamics Simulations 
Simulation details: All simulations were performed under the AMBER99SB-ILDN (60-62) 20 
forcefield as NPT ensembles at 310 K using periodic boundary conditions. Hydrogen atoms, 
consistent to pH 7, were added to the complex. Short range electrostatic and van der Waals 
interactions were truncated at 1.4 nm while long range electrostatics were treated with the particle-
mesh Ewald method and a long-range dispersion correction applied. A simulation box extending 
2 nm from the protein was filled with TIP3P waters and 150 mM Na and Cl ions added to attain a 25 
neutral charge overall. Pressure was controlled by the Berendsen barostat and temperature by the 
V-rescale thermostat. The simulations were integrated with a leap-frog algorithm over a 2 fs time 
step, constraining bond vibrations with the P-LINCS method. Structures were saved every 0.1 ns 
for analysis in each of the simulations over 100 ns. Simulation data were accumulated on the 
Bristol supercomputer BlueCrystal Phase 4, the BrisSynBio BlueGEM, and the UK 30 
supercomputer, ARCHER. 
Software. The GROMACS-2019.2 (24) suite of software was used to set up and perform the 
molecular dynamics simulations and analyses for BlueGEM and BlueCrystal Phase 4 runs and 
GROMACS-2019.1 (24) for the ARCHER runs. Molecular graphics manipulations and 
visualisations were performed using VMD-1.9.1 (63) and Chimera-1.10.2 (48) and movies made 35 
using VMD (63). 
 
  





Purification and quality control of SARS-CoV-2 spike protein. (A) Size-exclusion 
chromatogram of affinity-purified SARS-CoV-2 spike protein using a Superdex 200 column. 
Absorption was detected at 280 nm (blue line) and 260 nm (red line). Peak fractions are indicated. 5 
The first peak at 8.6 mL elution volume corresponds to the void volume of the column comprising 
negligible amounts of spike protein as confirmed by the SDS-PAGE analysis in  panel B (fractions 
1 and 2). The spike trimer elutes at 10.8 mL. (B) SDS PAGE analysis of the SEC fractions from 
panel A. Lane 1: input fraction, lane 2: molecular weight marker, lane 3-15: fractions 1 to 13 from 
SEC. (C) Negative stain EM of SEC peak fraction 7 (scale bar: 100 nm). In panels A and B peak 10 
fraction 7 is highlighted with a red box; this fraction was used for negative stain EM and cryo-EM. 
 
  





Cryo-EM image processing workflow. A motion-corrected cryo-EM micrograph is shown (scale 
bar 20 nm), reference-free 2D class averages (scale bar 10 nm), 3D classification and refinement 
resulting in cryo-EM maps corresponding to the open conformation and the closed conformation 5 
(not symmetrized and C3 symmetrized).  





Cryo-EM structure validation. Top left: Fourier Shell Correlation (FSC) curve after gold 
standard refinement. Top right: Cryo-EM reconstruction colored according to the local resolution 
from a side and top view. Below left: Orientation distribution of views that contributed to this map. 5 
Longer red rods represent orientations that comprise more particles. Below right: Cross-validation 
FSC curves for the refined model versus the final masked and unmasked maps, shown for (A) the 
closed unsymmetrized C1 map (B) the closed C3-symmetrized map and (C) the open conformation 
map. For the open conformation, the views distribution is shown on the right, next to the local 
resolution map.  10 





Cryo-EM structure of SARS-CoV-2 S in the open conformation. The 3.5 Å cryo-EM density 
of the SARS-CoV-2 spike trimer is shown (left). Monomers are colored in cyan, green and pink, 
respectively. A quasi-atomic model is depicted in a cartoon representation in a front (middle) and 5 
top view (right) using the same colors (c.f. Fig.1). RBDs were placed as rigid bodies, and LA was 
not included in the model. 
  





LA binding protein complexes. The structures of LA bound to SARS-CoV-2 S protein (this 
study, left), Streptococcus pneumoniae Fatty Acid Kinase (Fak) B3 (PDBID 6CNG (20), middle) 
and Aedes aegypti Odorant Binding Protein 22 (OBP22) (PDBID 6OGH, (21), right) are shown 5 
for comparison (top panel). Amino acids interacting with the polar headgroup of LA are labelled. 
Despite markedly different protein architectures, the conformation adopted by the LA in each 
complex is similar, featuring a pronounced kink in the structures (close-up views below).   
   
 10 
  




   
 
LA ligands bound to the SARS-CoV-2 spike RBDs. The three independent RBDs present in 
SARS-CoV-2 spike trimer are shown. Processing and refinement in C1 (no symmetry applied) 5 
results in tube-shaped density within all three RBDs, indicating that a LA ligand is present in each 
fatty acid-binding pocket. EM density is depicted as a mesh colored in grey. RBDs are colored 
cyan, green and pink (c.f. Figure 1). LA ligand is shown as sticks colored in orange.  The density 
of amino acid residues in the binding pocket surrounding LA in the C3 structure is shown for 
comparison in a clipped view (bottom right). 10 
 
  







Masked 3D classification focusing on the Receptor Binding Domain of the S glycoprotein into 5 
5 classes. Class 3 comprised 78.3% of all RBDs. This class presents LA bound RBD. The other 












Polybasic cleavage site deletion in SARS-CoV-2 spike. The construct used in this study has a 5 
RRAR to A deletion in the polybasic cleavage site (boxed in black). This site is part of a flexible 
loop in the S protein which is not observed by cryo-EM (circled in red in close-up view). 
Comparison of the LA-bound SARS-CoV-2 spike protein (cyan) and the ‘apo’ form (dark blue, 
PDBID 6VXX, RRAR->SGAG (7)) shown in a close up view superimposed on cryo-EM density 











Binding of spike glycoprotein and RBD to immobilized ACE2 ectodomain by surface 5 
plasmon resonance (SPR). Apo spike glycoprotein (A) and LA-bound spike (B) were diluted to 
concentrations between 40 nM and 160 nM and flowed over 50 RU of biotinylated ACE2 
immobilized on a streptavidin-coated sensor chip. Black lines correspond to a global fit of the data 
using a 1:1 binding model. Each experiment was repeated independently three times. All protein 
concentrations were used to calculate the KD, kon and koff values. For the RBD (C), 300 RU ACE2 10 











Binding of LA to immobilized RBD by surface plasmon resonance (SPR). LA was diluted to 5 
concentrations between 4 µM and 10 µM and flowed over 3,800 RU of biotinylated and lipidex-
treated RBD immobilized on a streptavidin-coated sensor chip. Black lines correspond to a global 
fit of the data using a 1:1 binding model. Each experiment was repeated independently three times. 
All LA concentrations were used to calculate the KD, kon and koff values. 
 10 
  





Superimposition of RBDs in OC43 S protein trimer and LA-bound SARS-CoV-2 S. The 
OC43 RBD colored in dark green and the LA-bound SARS-CoV-2 RBD colored in cyan were 
used for structure alignment. Two further RBDs in the trimer in OC43 S are colored in grey. 5 
Corresponding RBDs in the LA-bound SARS-CoV-2 S are colored in green and pink (c.f. Fig. 1). 
The three RBDs of OC43 are locked in a tightly packed conformation with close contacts at the 
RBD-RBD interfaces (PDBID 6NZK (18)). 
 
  10 





Spike protein RBD structures. LA-bound SARS-CoV-2 S RBD (cyan, this study, left) and RBDs 
of commonly circulating human coronaviruses 229E (PDBID 6U7H (27), middle) and NL63 
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Table S1.  
Cryo-EM data collection and refinement statistics. 
 Closed 
conformation,         
C3 symmetrized 
Closed 
conformation,          
C1 
Open    
conformation,         
C1 
Voltage (kV)  200  200 200 
Magnification (nominal) 130,000 130,000 130,000 
Pixel size (Å/pix) 1.05 (0.525) 1.05 (0.525) 1.05 (0.525) 
Flux (e- /pix/sec) 6.1 6.1 6.1 
Frames per exposure  55 55 55 
Exposure (e- /Å2) 60.5 60.5 60.5 
Defocus range (µm) -0.8 to -2  -0.8 to -2 -0.8 to -2 
Micrographs collected  3289 3289 3289 
Particles final 217,815 136,405 57,990 
Map sharpening B-factor (Å2) -86.8 -89 -87 
Masked resolution at 0.143 
FSC (Å)  









Amino acids  3096 3133 
Glycans 26 27 
Ligands 3 3 
RMSD bonds (Å)  0.013 0.008 
RMSD angles (º)  0.843 0.807 
Mean B-factors (Å2) 
Amino acids  25.25 32.78 
Ligands 36.91 38.86 
Ramachandran  
Favoured (%)  92.20 90.17 
Allowed (%)  7.80 9.66 
Outliers (%)  0.00 0.16 
Rotamer outliers (%)  3.27 5.84 
Clash score  4.16 4.26 
C-beta outliers (%)  0.00 0.00 
CaBLAM outliers (%)  3.46 4.31 
CC (mask)  0.84 0.84 
MolProbity score  2.07 2.33 
EMRinger score  3.59 3.79 
Model resolution (Å)  
0.5 FSC threshold  
2.9  3.1 




N-linked glycosylation sites in the SARS-CoV-2 spike protein  
WT SARS-CoV-2 spike *  Recombinant SARS-CoV-2 spike expressed in 
Predicted (UNIPROT) Freestyle 293F (7) ** Hi5 (this study) ** 
N17LT  N17LT 
N61VT N61VT N61VT 
N74GT   
N121NA  #   
N122AT N122AT N122AT 
N149KS   
N165CT N165CT N165CT 
N234IT N234IT N234IT 
N282GT N282GT N282GT 
N331IT N331IT N331IT 
N343AT N343AT N343AT 
N370SA  #   
N603TS N603TS  
N616CT N616CT N616CT 
N657NS N657NS  
N709NS N709NS N706NS 
N717FT N717FT N714FT 
N801FS N801FS N798FS 
N1074FT N1074FT N1071FT 
N1098GT N1098GT N1095GT 
N1134NT N1134NT N1131NT 
N1158HT   
N1173AS   
N1194ES   
*  YP_009724390.1 
**Sites lacking glycosylation in cryo-EM maps are omitted (boxes colored in grey). 
#   Predicted based on SARS-CoV spike protein  (7) 
 
 
  5 




Alignment of coronavirus S protein sequences (S-CryoEM denotes construct in this study) 
 

















Movie S1: Simulation of LA-bound SARS-CoV-2 S trimer colored in cyan, green and pink in the 
locked conformation, viewed from the side. LA is shown as spheres. 
 5 
Movie S2: Simulation of SARS-CoV-2 S trimer in the locked form, close up view of LA-bound 
pocket. LA is shown as spheres. Amino acids interacting with the ligand are shown as sticks. 
 
Movie S3: Simulation of SARS-CoV-2 S trimer colored in cyan, green and pink in the open form, 
viewed from the side. The RBD of one S monomer (colored in pink) adopts the ‘up’ position. LA 10 
is shown as spheres.  
 
Movie S4: Animated structure of LA-bound SARS-CoV-2 S trimer colored in cyan, green and 
pink. Morphing of apo S (PDBID 6VXX (7)) to LA-bound S is illustrated.   
 15 
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